Protein C Inhibitor (PCI), also known as Plasminogen Activator Inhibitor 3 (PAI3), is a member of the SERPIN family of proteinase inhibitors. It is produced in the liver as a single chain glycoprotein (mass of 57kD) and circulates in plasma at a concentration of 5ug/ml (~90nM). PCI is also found in urine in lower concentrations of 250ng/mL (~0.4 M). PCI is the primary inhibitor of activated Protein C (APC) in plasma but demonstrates a relatively broad specificity, also inhibiting thrombin, FXa, FXIa, kallikrein, tPA, urokinase, prostate specific antigen, acrosin, chymotrypsin and trypsin. The preferred enzyme target for PCI appears to be thrombin and this interaction is increased by more than 100 fold in the presence of thrombomodulin.
Like ATIII and HCII, the inhibitory activity of PCI towards some of these enzymes is stimulated by high concentrations of heparin (5U/ml) which can accelerate the rate of inactivation as much as 50 fold. Enzyme inhibition by PCI occurs through proteolytic cleavage at Arg354-Ser355 and subsequent rapid formation of a stable, inactive 1:1 enzyme-PCI complex. Interaction with APC results in an SDS-stable APC-PCI complex of 102kD.
Antibodies for 5x96 well plates
P9102-39A1: Capture Antibody 1x500ul
Affinity purified goat anti-human Protein C Inhibitor (PCI) IgG for coating plates. Supplied as a liquid in 50% glycerol.
P9102-39A2: Detecting Antibody (HRP) 1x500ul
Peroxidase labeled anti-human Protein C Inhibitor for detection of captured PCI. Supplied as a liquid in 50% glycerol.
Storage and Stability:
May be stored at 4 degrees C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.